EC Number   |
|---|
    1.3.5.2 | - |
| 1.3.5.2 | all compounds that were found to be inhibitors are predicted, using SPROUT, a software package for structure-based drug discovery and lead optimization, to bind in a manner similar to that observed for compound (2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide, with the planar headgroup making direct hydrogen bonds to residues Arg265, His185, and Tyr528. The biphenyl tail of each inhibitor is predicted to bind in the large hydrophobic region of the binding cavity, in a fashion analogous to that found for these inhibitors in human DHODH. The substituted biaryl moiety present in these inhibitors is predicted to occupy the binding cavity more extensively compared to that of compound (2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide |
| 1.3.5.2 | comparison of ligand-free forms of Schistosoma mansoni DHODH and human DHODH, which undergo different rearrangements in solution |
| 1.3.5.2 | homology modeling, presence of an additional protuberant domain predicted to fold as a flexible loop and absent in the other known class 2 DHODHs. The ligand-free forms of Schistosoma mansoni DHODH and human DHODH undergo different rearrangements in solution |
| 1.3.5.2 | in complex with inhibitors (2Z)-N-(biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide, (2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide, (2Z)-2-cyano-N-(2,2'-dichlorobiphenyl-4-yl)-3-hydroxybut-2-enamide, and (2Z)-2-cyano-N-(3'-ethoxybiphenyl-4-yl)-3-hydroxybut-2-enamide |
| 1.3.5.2 | in complex with inhibitors 2-[(2,5-dichlorophenyl)sulfanyl]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol and 2-[(2,5-dichlorophenyl)sulfanyl]-5-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol. bindung induces a structural change in the N-terminal helix. Comparison with binding to Plasmodium falciparum enzyme |
| 1.3.5.2 | in complex with inhibitors 5-methyl-N-(naphthalen-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, and 5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine to 2.0 A, 2.4 A, and 2.5 A resolution, respectively |
| 1.3.5.2 | in complex with inhibitors 6-chloro-2-(2'-fluorobiphenyl-4-yl)quinoline-4-carboxylic acid and and without any bound inhibitor, to 2.3 A, 2.1 A, and 3.0 A resolution, respectively. Inhibitor 5-methoxy-2-[(4-phenoxyphenyl)amino]benzoic acid 5-methoxy-2-[(4-phenoxyphenyl)amino]benzoic acid interacts with residue Y356. Loop region of residues L68-R72 may interfere with inhibitor/cofactor binding. Loop region N212-L224 may be important for the enzymatic reaction |
| 1.3.5.2 | in complex with low molecular weight compounds that inhibit the enzyme in the nanomolar range, by hanging-drop vapor diffusion method, to 2.15 A resolution |
| 1.3.5.2 | mutant DELTA1-29 in complex with brequinar and with atovaquone |
